ABSTRACT
The objective of the described research effort was to identify a novel serotonin and norepinephrine reuptake inhibitor (SNRI) with improved norepinephrine transporter activity and acceptable metabolic stability and exhibiting minimal drug-drug interaction. We describe herein the discovery of a series of 3-substituted pyrrolidines, exemplified by compound 1. Compound 1 is a selective SNRI in vitro and in vivo, has favorable ADME properties, and retains inhibitory activity in the formalin model of pain behavior. Compound 1 thus represents a potential new probe to explore utility of SNRIs in central nervous system disorders, including chronic pain conditions.
ABSTRACT
In the last years, there has been an increasing demand on the development of quantitative assays for determination of enantiopurity. Herein, we present a methodology based on a direct linking of an atmospheric pressure ionization mass spectrometer (MS-APCI) with a high-performance liquid chromatography HPLC (DAD) system, operated under normal-phase mode and without post-column addition of MS-compatible solvents, which provides the high specificity/selectivity (identification of isomers in complex mixtures) and accuracy (1-2% area level) required for daily chiral studies. As result of the success of our screen, the preparation of individual enantiomers or the racemic mixture in our Drug Discovery Research Laboratories at Lilly, Spain is usually not required. Therefore, additional non-valuable synthetic work is eliminated.
